Article Sidebar
Published:
Jun 25, 2020DOI:
10.4314/tjpr.v19i5.3Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
An oral vaccine against CVA16 (Coxsackievirus A16) was developed by constructing a recombinant Lactococcus lactis
Abstract
Purpose: To develop an oral vaccine against CVA16 (Coxsackievirus A16) by constructing a recombinant Lactococcus lactis that expresses VP1 from CVA16.
Method: An oral CVA16 vaccine was prepared by expressing CVA16 VP1 protein with Lactococcus lactis. CVA16 VP1 gene was incorporated into a Lactobacillus expression vector, namely, pNZ8148, and then expressed in NZ9000, a food-grade lactic acid bacterium which serves as a carrier for oral vaccines.
Results: There was statistically significant difference in CVA16-specific IgG antibody level between NZ9000-pNZ8148-CVA16-VP1 group (0.49 ± 0.05) and control group (0.05 ± 0.00) when the antiserum was diluted 1:10 (t = 19.84; p < 0.05). Furthermore, the level of CVA16-specific IgA antibody in NZ9000- pNZ8148-CVA16-VP1 group (0.17 ± 0.02) was significantly higher than in control group (0.05 ± 0.00) following antiserum dilution of 1:10 (t =12.08; p < 0.05).
Conclusion: A CVA16 oral vaccine made from Lactobacillus elicits protective antibodies against CVA16. Thus, it is a potential as oral vaccine against CVA16 but further studies in vivo are required to ascertain its safety and effectiveness.
Keywords: Coxsackievirus A16, Hand, foot and mouth disease, Lactococcus lactis, Oral vaccine, Enterovirus 71
